Yongho Park

Yongho Park

Auto-generated profile, based on publicly available information

Yongho Park

College of Medicine, University of Central Florida, Orlando, Florida

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2019 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
MVMichael E. Vinyard
Michael E. Vinyard
CSCindy Su
Cindy Su
ASAllison P. Siegenfeld
Allison P. Siegenfeld
AWAmanda L. Waterbury
Amanda L. Waterbury
AFAllyson M. Freedy
Allyson M. Freedy
BLBrian B. Liau
Brian B. Liau

25 February 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YPYongho Park
Yongho Park
YKYumi Koga
Yumi Koga
CSCindy Su
Cindy Su
AWAmanda L. Waterbury
Amanda L. Waterbury
CJChristopher L. Johnny
Christopher L. Johnny
BLBrian B. Liau
Brian B. Liau

12 June 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
ELEunkyung Lee
Eunkyung Lee
YPYongho Park
Yongho Park
DLDavid Li
David Li
ARAlice Rodriguez-Fuguet
Alice Rodriguez-Fuguet
XWXiaochuan Wang
Xiaochuan Wang
Wencai ZhangWencai Zhang
Wencai Zhang
Recent preclinical studies have linked antidepressants (AD) to their potential anticancer effects in multiple cancers, but the impact on lung cancer remains unclear. This meta-analysis examined the associations between ADs and lung cancer incidence and survival. The Web of Science, Medline, CINAHL, and PsycINFO databases were searched to identify eligible studies published by June 2022. We conducted a meta-analysis using a random-effects model to compare the pooled risk ratio (RR) and 95% confidence interval (CI) in those treated with or without ADs. Heterogeneity was examined using Cochran Q test and inconsistency I2 statistics. The methodologic quality of the selected studies was assessed using the Newcastle-Ottawa Scale for observational studies. Our analysis, including 11 publications involving 1,200,885 participants, showed that AD use increased lung cancer risk by 11% (RR = 1.11; 95% CI = 1.02–1.20; I2 = 65.03%; n = 6) but was not associated with overall survival (RR = 1.04; 95% CI = 0.75–1.45; I2 = 83.40%; n = 4). One study examined cancer-specific survival. Subgroup analysis showed that serotonin and norepinephrine reuptake inhibitors (SNRIs) were associated with an increased lung cancer risk by 38% (RR = 1.38; 95% CI = 1.07–1.78; n = 2). The quality of selected studies was good (n = 5) to fair (n = 6). Our data analysis suggests that SNRIs were associated with an elevated risk of lung cancer, raising concerns regarding the use of AD treatment in patients vulnerable to lung cancer. The effects of ADs—particularly SNRIs—and their interplay with cigarette use and lung cancer risk in vulnerable patients merits further study. Significance: In this meta-analysis of 11 observational studies, we found evidence of a statistically significant association between the use of certain ADs and lung cancer risk. This effect merits further study, particularly as it relates to known environmental and behavioral drivers of lung cancer risk, such as air pollution and cigarette smoke.

17 August 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YKYumi Koga
Yumi Koga
EHEileen M. Hoang
Eileen M. Hoang
YPYongho Park
Yongho Park
AKAlexander F.A. Keszei
Alexander F.A. Keszei
JMJason Murray
Jason Murray
BLBrian B. Liau
Brian B. Liau

25 February 2019 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
YPYongho Park
Yongho Park
YKYumi Koga
Yumi Koga
CSCindy Su
Cindy Su
AWAmanda L. Waterbury
Amanda L. Waterbury
CJChristopher L. Johnny
Christopher L. Johnny
BLBrian B. Liau
Brian B. Liau